TARO-ETODOLAC 300 MG
ETODOLAC : 300 MG · DIN 02242915 · TARO PHARMACEUTICALS INC
Health Canada status: CANCELLED POST MARKET
What is TARO-ETODOLAC?
TARO-ETODOLAC 300 MG contains ETODOLAC : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02242915, held by TARO PHARMACEUTICALS INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 03-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02242915 |
|---|---|
| Brand name | TARO-ETODOLAC |
| Generic / active ingredient | ETODOLAC : 300 MG |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 300 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AB08 ETODOLAC |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 03-Feb-2022 |
| Original market date | 2000-10-20 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M01AB08 ETODOLAC. 0 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ETODOLAC | 200 MG | CAPSULE | APOTEX INC | APPROVED | DIN 02231965 |
| ETODOLAC | 200 MG | CAPSULE | AA PHARMA INC | DORMANT | DIN 02232317 |
| ETODOLAC | 300 MG | CAPSULE | AA PHARMA INC | DORMANT | DIN 02232318 |
| ETODOLAC | 300 MG | CAPSULE | APOTEX INC | APPROVED | DIN 02231967 |
| GEN-ETODOLAC 200MG | 200 MG | CAPSULE | GENPHARM ULC | CANCELLED POST MARKET | DIN 02239319 |
| GEN-ETODOLAC 300MG | 300 MG | CAPSULE | GENPHARM ULC | CANCELLED POST MARKET | DIN 02239320 |
| NOVO-ETODOLAC 200 MG | 200 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED PRE MARKET | DIN 02242205 |
| NOVO-ETODOLAC 300 MG | 300 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED PRE MARKET | DIN 02242206 |
| TARO-ETODOLAC 200 MG | 200 MG | CAPSULE | TARO PHARMACEUTICALS INC | CANCELLED POST MARKET | DIN 02242914 |
| ULTRADOL - CAP 200MG | 200 MG | CAPSULE | PROCTER & GAMBLE PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02142023 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.